GlassScriptPhysician profile
William M Corrao
NPI 1033132816
$166,211.36
in general payments reported to CMS, 2019-2025
15 companies · $30.11 in 2025
The $30.11 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59K · 2020: $35K · 2021: $36K · 2022: $14K · 2023: $22K · 2025: $30.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Food and Beverage: $540 · Travel and Lodging: $70.74 · Education: $57.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,775.00 |
| Food and Beverage | $539.63 |
| Travel and Lodging | $70.74 |
| Education | $57.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $135,055.53 | 2019-2023 | Nucala, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30,146.89 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $258.34 | 2019-2022 | |
| Genzyme Corporation | $217.20 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $78.18 | 2019-2020 | |
| Mylan Specialty L.P. | $73.84 | 2019-2020 | |
| Grifols USA, LLC | $57.37 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $55.31 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $54.19 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $53.24 | 2019 | |
| Jazz Pharmaceuticals INC. | $47.56 | 2019-2020 | |
| Insmed, INC. | $36.64 | 2019 | |
| Merck Sharp & Dohme LLC | $30.11 | 2025 | Zerbaxa |
| Csl Behring | $29.28 | 2020 | |
| United Therapeutics Corporation | $17.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Corrao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.